30 results about "B16 melanoma" patented technology

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

The invention relates to an escherichia coli anti-tumor targeted engineering strain, and a building method and application thereof. The escherichia coli anti-tumor targeted engineering strain, i.e., Escherichia coli Nissle 1917(Tum-5) is preserved in CCTCC (China Center for Type Culture Collection), and the preservation number is CCTCC NO:M 2017345. The anti-tumor targeted engineering strain contains an anti-tumor secretion express vector pET28a-Pvhb-SUMO-Tum 5; and the soluble expression and the secretory expression of anti-tumor blood vessels of tumstatin can be realized to generate an active region Tum-5. The invention also comprises the building method of the escherichia coli anti-tumor targeted engineering strain, and application of the escherichia coli anti-tumor targeted engineeringstrain to preparation of anti-tumor medicine. The tumor inhibiting rate of the escherichia coli anti-tumor targeted engineering strain on B16-bearing melanoma C57BL/6 mice reaches up to 52.95 percent.

A cosmetic composition for topical application to skin is provided. The cosmetic composition includes vitamin B3 compound, a ricinoleate compound and a dermatologically acceptable carrier. The vitamin B3 compound and the ricinoleate beneficially or even synergistically up-regulate proteasomal protease activity as evidenced by a higher observed net luminescence value relative to the calculated net luminescence value in B16 melanoma cells.

The invention belongs to the technical fields of medicaments and foods and relates to an artocarpus hypargyreus hance extract and a preparation method and application thereof. In the artocarpus hypargyreus hance extract, the content of an isopentenyl-substituted flavonoid compound is 20 to 40 weight percent. The preparation method comprises the following steps; extracting stems and branches of artocarpus hypargyreus hance serving as a raw material by a solvent to prepare a total extract; dissolving the total extract in water, extracting with a halogenated solvent and an ester solvent in sequence; and taking an extraction phase of the ester solvent, and drying after reclaiming the solvent to obtain the artocarpus hypargyreus hance extract. Through activity tests such as tyrosinase in vitro, B16 melanoma cells, DPPH clearing and the like, results show that the artocarpus hypargyreus hance extract has strong effects of inhibiting the generation of the tyrosinase and melanin and clearing free radicals, can be used as a melanin inhibitor, a whitening agent or a natural antioxidant, and is applied to the fields of medicament, daily chemical engineering and food.

The invention relates to supernatant cultivated by DCIK cells and an application thereof. The supernatant and a preparation of freeze-dried powder prepared by frozen, dried and concentrated supernatant have good anti-tumor activity in tumor therapy. The supernatant cultivated by DCIK cells contains a series of mixtures of cytokines with biological activity which directly act on cell lines cultivated in vitro, thereby causing the forms of the cell lines such as mice melanoma B16 and THP-1 etc. to be affected and producing growth inhibition. The anti-tumor in vivo experiment shows that the supernatant cultivated by DCIK cells and the preparation of freeze-dried powder thereof can obviously inhibit the growth of the mouse melanoma B16 inoculated subcutaneously without obvious side effect. The invention fully proves the prospects of application and research of supernatant cultivated by DCIK cells, and paves the new way for the research of anti-tumor drugs.

The present invention discloses an anti-TLP2 antibody. Said anti-TLR2 antibody can inhibit tumor, specially can inhibit the metastasis of B16 melanin tumor. Said anti-TLR2 antibody not only can block TLR2 activity, but also can obviously reduce number of metastatic foci of lung. At the same time, said invention finds that the bleomycin and said anti-TLR2 antibody have good synergistic action.

An application of the extract and active comonents of daturae flower in preparing the medicines for preventing and treating tumor, such as sarcoma and melanoma, is disclosed.

The invention discloses a whitening and freckle-removing essence and a preparation method of the whitening and freckle-removing essence. Comprising the following raw materials in parts by mass: 25 to 35 parts of a humectant, 2 to 3 parts of nicotinamide, 1 to 3 parts of nonapeptide-1, 2 to 3 parts of cystosella rubra extract, 2 to 4 parts of yeast extract, 2 to 3 parts of resveratrol, 0.5 to 1 part of 4-butylresorcinol, 0.3 to 0.5 part of hydrophilic colloid and 47.5 to 65.2 parts of deionized water. According to the whitening and freckle-removing essence disclosed by the invention, the 4-butylresorcinol has an inhibiting effect on generation of melanin, B16 melanoma cells synthesized by directly inhibiting the activity of tyrosinase and inhibiting the tyrosinase are not generated, and any cytotoxicity and irritation are not generated. Meanwhile, the added nonapeptide-1, resveratrol and yeast extract are whitening substances with very high biological activity, have the effects of whitening, brightening and fading spots, can accelerate melanin decomposition and reduce skin pigmentation, and have the effects of whitening and fading spots.

The invention provides construction of a double-gene co-expression plasmid pEgr-IL18-B7.2 and an application of the double-gene co-expression plasmid pEgr-IL18-B7.2 to radiation-combined tumor resisting. According to the tumor gene-radiotherapy theory and the radiation induction expression characteristics of Egr-1 genes, the double-gene co-expression plasmid pEgr-IL18-B7.2 is constructed on the basis of B7.2 genes of a clone mouse. IL18 genes with the anti-tumor effect and costimulatory-molecule B7-2 genes are transferred into tumor cells through double-gene carriers; the construction and the application further prove that low-dosage radiation can induce radiation-sensitive promoters, and therefore the finer-control effect is achieved on multi-gene expression; radiation-induced double-gene expression shows a certain time-interval and dose-effect rule. According to a test, the constructed double-gene plasmid is further injected into a tumor body of a B16 melanoma transplanted to the mouse, local radiotherapy is carried out in cooperation, and the tumor inhibiting effect more remarkable than that of pure radiotherapy is shown, and preliminary discussion is made for possible mechanisms in the immunology aspect.

Here we show that SEG/SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG/SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p<0.001). In vaccination studies, DQ8 tg mice showed a surge in IFNγ serum levels reaching 3000 fold above baseline devoid of a parallel spike in TNFα levels above baseline levels. Presentation of the SEG/SEI superantigen from a MHC-DQ8 platform, therefore, augments the therapeutic index of these SAgs inducing a tumoricidal response against Lewis lung carcinoma and B16 melanoma accompanied by a sharp increase of therapeutic IFNγ levels absent toxic levels of TNFα.

The present invention relates to an isoxazole derivative, the compound of formula (I)

herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027.

Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells. Moreover, GIT27-NO induced the production of reactive oxygen species which can be neutralized by antioxidant N-acetyl cysteine (NAC), indicating that reactive oxygen species (ROS) are at least partly involved in the reduction of cell viability. The anti-tumor activity of GIT27-NO is mediated through activation of MAP kinases (ERK1/2, p38 and JNK) in cell-specific manner. The role of MAP kinases was further confirmed by specific inhibitors of these molecules, PD98059, SB202190, and SP600125. Finally, in vivo treatment with GIT27-NO significantly reduced tumor growth in syngeneic C57BL/6 mice implanted with B16 melanoma.

The invention discloses a PTD-SOD-MUTANT protein which is a fusion protein composed of a protein transduction structural domain PTD and SOD derived from thermophilic bacteria HB27, wherein I27L and D107A double mutation occurs in an SOD amino acid sequence. The PTD-SOD-MUTANT protein has the advantages of being good in thermal stability, high in activity and capable of penetrating through cell membranes to enter cells and the like. In-vitro and in-vivo experiments show that the protein has a very strong proliferation inhibition effect on mouse B16 melanoma cells and mouse malignant melanoma, and the protein and adriamycin (DOX) have a synergistic interaction effect on tumor cells. The PTD-SOD-MUTANT protein can be used as a pharmaceutical composition, a cosmetic active component, a food additive and the like, and has a great application value and wide application prospect in the fields of drug research and development, daily necessities, foods and the like.

The invention relates to a Uighur medicine compound for leucoderma and a preparation method thereof. The compound is prepared from the following medicinal materials: herb of carum carvi, fructus psoraleae, puncture vine caltrop fruit, seed of ajowan-caraway, root of operculina turpethum; oral dosage forms such as oral liquid, syrup, granules, hard capsules and tablets are prepared by the methods of solvent extraction, impurity removal, concentration and drying and by adopting proper accessories. According to the Uighur medicine compound and the preparation method thereof provided by the invention, the Uighur medicine compound for leucoderma is prepared by a modern extraction method according to the theory of Uighur medicine and in combination with the characteristics of national medicinesand long-term civil clinical practice, the efficacy is enhanced, and the bioavailability is improved. In-vitro activity experiments indicate that different dosage forms of the Uighur medicine compoundfor leucoderma prepared by the method influence the morphology of mouse B16 melanoma cells to different degrees and realize a concentration dependence activation effect on the cell activity and the melanin synthetic quantity. Experimental results indicate that different dosage forms of the Uighur medicine compound for leucoderma all show very strong ability of activating B16 melanoma cells and promoting melanin formation and can be used for treating leucoderma.

The invention discloses a new application of a peach blossom blood purifying pill compound preparation to preparation of drugs for curing chloasma and freckles. The experiment proves that the peach blossom blood purifying pill preparation can obviously inhibit synthesis of melanin of mouse B16 melanoma cells, while has no effect on the activation of tyramine oxidase, and the peach blossom blood purifying pill preparation has the good effect on treatment of pigmented dermatoses can be proved. Clinical research verifies that the peach blossom blood purifying pill preparation adopts vitamin E asa control group when being used for treating chloasma, the effect of the peach blossom blood purifying pill preparation on treating chloasma is obviously superior to the effect of taking vitamin drugsorally, and the peach blossom blood purifying pill preparation has the better safety. The clinic research verifies that when the peach blossom blood purifying pill preparation is used for treating freckles, oral taking vitamin E and externally applying hydroquinone are taken as the control group, the total effective rate is improved remarkably, and no obvious adverse drug reaction occurs. The above research proves that the application field of the peach blossom blood purifying pill to treatment of chloasma and freckles is developed, the new treatment drug is provided for the field of chloasmaand freckle skin diseases, and the peach blossom blood purifying pill compound preparation has the very good clinic research meaning.

A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

The invention relates to the technical field of health-care food, in particular to a composition with whitening and acne-removing effects as well as a preparation method and application of the composition. According to the composition, medicinal and edible raw materials such as radix puerariae, radix platycodi, liquorice root, radix angelicae dahuricae and fructus momordicae are compounded according to specific proportions; the experiment shows that the composition provided by the invention has a significant inhibitory effect on melanin synthesis of B16 melanoma cells and activity of tyrosinase, can remarkably improve the ultraviolet-induced skin pigmentation of mice and has an obvious inhibitory effect on acne pathogenic bacteria such as propionibacterium, staphylococcus epidermidis and staphylococcus aureus; in addition, the composition has an obvious curative effect on rabbit ear acne. The results show that the composition disclosed by the invention has remarkable whitening and acne-removing effects.